High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study

• Published in: Journal of translational medicine Vol. 19; no. 1; p. 92
• Main Authors: Sumiyoshi, Issei, Okabe, Takahiro, Togo, Shinsaku, Takagi, Haruhi, Motomura, Hiroaki, Ochi, Yusuke, Shimada, Naoko, Haraguchi, Mizuki, Shibayama, Rina, Fujimoto, Yuichi, Watanabe, Junko, Iwai, Moe, Kadoya, Kotaro, Iwakami, Shin-Ichiro, Takahashi, Kazuhisa
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 28-02-2021; BioMed Central; BMC
• Subjects: Absolute lymphocyte count; Antibodies; Apoptosis; B7-H1 Antigen; Biomarkers; Blood; Blood cell count; Carcinoma, Non-Small-Cell Lung - drug therapy; Cell death; Cell number; Cloning; Cytotoxicity; Drug therapy; Health aspects; Humans; Immune checkpoint inhibitors; Immunogenic cell death; Immunogenicity; Leukocytes (neutrophilic); Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lymphocyte Count; Lymphocytes; Neutrophil-to-lymphocyte ratio; Non-small cell lung carcinoma; Non-small-cell lung cancer; Observational studies; Paclitaxel; Patient outcomes; Patients; PD-1 protein; PD-L1 protein; Pemetrexed; Pemetrexed - therapeutic use; Prognosis; Programmed cell death-1; Reagents; Small cell lung carcinoma; Statistical analysis; Tumors; Variance analysis; Japan; United States > US; California; Programmed death-ligand 1; Neutrophil-to-lymphocyte ratio; Absolute lymphocyte count; Non-small-cell lung cancer; Programmed cell death-1; Pemetrexed; Immunogenic cell death
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-021-02761-1

Regimens combining pemetrexed (PEM) and immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are widely used for the treatment of advanced non-squamous non-small-cell lung cancer (NSq-NSCLC). Recently, PEM was shown to induce immunogenic cell death (ICD) and to enhance immune-regulatory genes. Some patients demonstrate an extremely long-term response to PEM. It is possible that the continued response in these patients is dependent on not only the pharmacological induction of cytotoxic cell death but also antitumor immunity. However, factors that can predict outcomes associated with long-term PEM administration using blood test results have not yet been elucidated. We investigated the clinical characteristics and predictive factors in patients with advanced NSq-NSCLC who underwent long-term PEM maintenance therapy.
In total, 504 patients with advanced NSq-NSCLC who received PEM combination therapy/monotherapy (n = 414) or paclitaxel (PTX) combination therapy (n = 90) between January 2010 and November 2019 were recruited; 381 patients were retained for the final analysis. Patients treated with PEM (n = 301) were divided into subgroups according to the total cycles of PEM (≥ 17 [n = 25] for the long-term administration group and ≤ 16 [n = 276] for the intermediate/short-term group) and compared with another population (n = 80) treated with PTX combination regimen. We investigated clinical features and predictive biomarkers, focusing on immune-regulatory factors, absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and PD-1 and PD-L1 expression, to predict long-term response to PEM.
The long-term PEM administration group exhibited a higher ALC and a lower NLR than the shorter-term group did. Both these markers displayed greater association with progression-free survival and overall survival in the PEM combination therapy group than in the PTX combination therapy group. Increased PD-1 lymphocytes were associated with the long-term PEM response group, as PD-L1 expression in tumors was associated with a high incidence of immune-related adverse effects following ICI administration.
ALC, NLR, and PD-1 expression are PEM-mediated predictive biomarkers that are indirectly related to tumor immunity and can provide useful predictive information on the long-term response to PEM in patients with NSq-NSCLC.